Key Highlights

  • Third-quarter Revenue reached USD 33.6 million, up roughly 14% (calculated) from USD 29.4 million, with product revenue climbing 15% to USD 23.7 million.
  • Quarterly losses shrank to USD 14.7 million (USD 0.78 a share) from USD 17.8 million (USD 1.00 a share) a year earlier.
  • Gross profit totaled USD 13.7 million, equal to a Margin near 40.7% (calculated), up from roughly 39.4% a year before, helped by service margins.
  • A USD 100 million term Loan from Perceptive Credit sits against USD 140.7 million of cash, equivalents, restricted cash and short-term investments reported at September 30, 2026.

Console Placements and Consumables Drive the Top Line

Outset Medical (NASDAQ:OM) published its quarterly results on November 4, 2026, for the period ending September 30. The company markets the Tablo Hemodialysis System, a dialysis platform that requires only an electrical outlet and tap water, chiefly to hospitals and other acute care providers. Product revenue increased USD 3.1 million, made up of USD 2.1 million more from consoles and USD 1.0 million more from consumables. Service and other income climbed 11.6% (calculated), reaching USD 9.9 million as the installed base expanded. Over nine months, revenue came to USD 93.1 million against USD 90.6 million, though product revenue slipped 1% on weaker consumables.

Leaner Sales Spending Narrows the Operating Loss

Margins did part of the work: gross margin rose 1.3 points for the quarter and 3.8 points for nine months. Management credited better service margins, even though consumables, which carry more margin, made up a smaller share of sales. Operating expenses totaled USD 25.9 million, versus USD 27.4 million before, with sales and Marketing down to USD 11.7 million from USD 13.6 million thanks to fewer staff and reduced travel. Research and Development rose to USD 5.9 million, a change tied to consulting. The operating loss shrank to USD 12.3 million from USD 15.8 million, but interest expense of USD 3.5 million still weighed. The nine-month net loss was USD 51.6 million, down from USD 62.2 million.

Cash Runway, Term Loan Conditions and Legal Expenses

Operating cash outflow for nine months narrowed to USD 32.9 million from USD 36.8 million. The accumulated Deficit reached USD 1.2 billion, and management believes existing cash and sales meet needs for at least 12 months. The Perceptive Facility carries covenants, including a minimum cash balance. An extra USD 25 million becomes available until July 14, 2027 if a revenue milestone is met, a condition amended in August 2026. General and administrative costs for nine months rose on legal spending tied to a stockholder class action and related derivative suits. Management also expects operating losses to persist for a while as it invests in growth.

Where Things Stand

The company is not there yet. Outset Medical (NASDAQ:OM) still lost about USD 14.7 million in the quarter, although the loss narrowed through cost discipline alongside revenue growth of about 14% (calculated). Gross margin near 41% is rising, and USD 140.7 million of cash supports at least 12 months according to management. The risks include the USD 100 million term loan with its minimum cash covenant, customers delaying Capital purchases and continuing legal costs. Next markers are whether console sales keep rising, whether consumables recover and whether the revenue milestone releasing the extra USD 25 million is reached.